R ecently, we reported that systemically administered tyramine induced forearm vasodilation rather than vasoconstriction, despite eliciting an increase in norepinephrine spillover. 1 This paradoxical effect of tyramine was associated with an increase in plasma dopamine, which could be responsible for the vasodilation. We hypothesized that tyramine increased plasma dopamine either by inducing its release from sympathetic nerve endings 2, 3 or by enzymatic (via the hepatic cytochrome P450 enzyme) 4 or nonenzymatic in vivo conversion of tyramine to dopamine. Alternatively, Goldstein et al proposed that increased dopamine could be the result of contamination in the tyramine infusate. 5 We did find that the tyramine solution used in our previous studies was contaminated with 0.7% to 1% of dopamine, 6 but it was unclear whether this degree of contamination would explain the vasodilation and increased plasma dopamine observed during tyramine infusion.
To test these possibilities, we obtained a lyophilized tyramine preparation free of dopamine contamination and evaluated its effects on forearm and systemic hemodynamics and on plasma levels of dopamine and other catechols. We used a systemic infusion of norepinephrine as control. If tyramine induces the release of dopamine, or is converted in vivo to dopamine, then infusion of dopamine-free tyramine should still increase plasma dopamine levels and produce vasodilation.
Methods

Subjects
The study group consisted of 8 healthy subjects, 21 to 45 years of age (35Ϯ3). All investigational procedures were approved by the Vanderbilt institutional review board, and subjects gave informed consent before the study. All studies were performed at the clinical research center at Vanderbilt University. Subjects were studied while supine after fasting for Ն4 hours in a quiet, partially darkened room. Subjects restrained from food and beverages containing monoamines and caffeine for Ն24 hours.
Instrumentation and Measurements
Two large antecubital veins were catheterized: one for blood sampling and the other for drug infusion. Forearm blood flow was measured in the side ipsilateral to blood sampling using venous occlusion plethysmography as described previously. 7 Basal cardiac output (CO) was measured by the acetylene rebreathing method as described previously. 8 Breath-by-breath gas analysis was conducted using an automated SensorMedics 2200 metabolic cart (SensorMedics). A thoracic bioimpedance measurement device (KIM4; Heinemann & Gregory) was used for continuous monitoring of stroke volume and to calculate relative changes in CO and systemic vascular resistance (SVR) produced during drug infusions. Blood pressure (BP) was measured by an automated sphygmomanometer (Vital-Guard 450C; Ivy Biomedical Systems, Inc.). All signals were digitized at a sampling rate of 500 Hz using DI-720USB and Windaq Proϩ software (DATAQ Instruments) and processed with user software written in PV-Wave (Visual Numerics Inc).
Mean BP was calculated as diastolic BPϩ1/3(systolic BPϪdia-stolic BP). The mean BP used for continuous CO determinations was derived from the integral of the finger BP waveform. Forearm vascular resistance was calculated as mean BP divided by forearm blood flow and expressed in units of mm HgϫmL Ϫ1 ϫdL (tissue) Ϫ1 ϫminutes Ϫ1 . CO was calculated as stroke volumeϫheart rate. SVR was calculated as mean BP/COϫ80 and expressed as dyne s/cm 5 .
Effect of Drugs on Plasma Catecholamines and Hemodynamics
Subjects rested quietly for Ն30 minutes after instrumentation. Baseline measurements were then taken after a 5-minute saline infusion at 30 mL/h. Tyramine (lyophilized tyramine HCl, 80% free base, diluted in 0.9% saline) was then infused intravenously at increasing doses for 5 minutes each (0.25, 0.5, 0.75, 1.0, 1.25, and 2.0 mg/min) until a rise in systolic BP of Ϸ25 mm Hg was obtained. After a 45-minute rest period, baseline measurements were repeated. Then norepinephrine (norepinephrine bitartarate, 50% free base dilute in 5% dextrose in water) was infused at increasing doses for 5 minutes each (0.5, 1.0, 2.0, 3.0, 4.0, and 8.0 g/min) until a rise in systolic BP of Ϸ25 mm Hg was obtained. Tyramine and norepinephrine were diluted immediately before each study and kept at 4°C until use. Bags and lines containing drug were covered with aluminum foil to avoid possible light-dependent oxidation. A total of 5 mL of infusate was obtained before and after the end of the infusion to measure tyramine and dopamine concentrations. These samples were handled in the same manner as blood samples for catecholamine determinations.
Plasma for catecholamines were stored at Ϫ70°C and assayed for norepinephrine, epinephrine, dopamine, dihydroxyphenylglycol (DHPG), dihydroxyphenylalanine, and dihydroxyphenylacetic acid (DOPAC) by high-performance liquid chromatography as described previously. 9 We confirmed that tyramine did not interfere with dopamine or other catecholamine assays.
Drugs and Statistical Analysis
Tyramine in lyophilized form was purchased from Clinalfa. Norepinephrine was obtained from our local pharmacy. Results are expressed as meanϮSEM. Paired or nonpaired 2-sided t test were used for intraindividual and interindividual comparisons, respectively, as appropriate. One-way ANOVA for repeated measurements (ANOVArm) was used to determine dose-response effect of drugs on the various parameters measured. Data were analyzed using Graph Pad Prism (version 4.03; GraphPad Software Inc). A P value Ͻ0.05 was considered statistically significant.
Results
Subjects' mean body mass index was 26Ϯ1.5 kg m 2 , and their weight and height were 78Ϯ7 kg and 1.72Ϯ0.035 m, respectively. The mean dose of tyramine and norepinephrine required to increase systolic BP by 25 mm Hg was 1.38Ϯ0.13 mg/min and 4.25Ϯ0.6 g/min, respectively. Hemodynamic and neurohumoral changes are shown in the Table. No side effects were reported.
Hemodynamic Responses
Tyramine increased systolic and diastolic BP in a doseresponse fashion (ANOVArm; PϽ0.001 and PϽ0.003, respectively). Heart rate decreased by 6Ϯ1 bpm during the maximal dose (PϽ0.008; Table) but not in a dose-dependent fashion (ANOVArm; Pϭ0.6).
Forearm blood flow and forearm vascular resistance did not change significantly during intravenous infusion of tyra- mine, despite a significant increase in mean BP and SVR (Figure 1 ; Table) . Resting supine CO, measured by the acetylene rebreathing method, was 4.2Ϯ0.5 L/min (measurements could not be obtained for technical reasons in 3 subjects). Tyramine did not alter CO determined by thoracic impedance (6.8Ϯ0.6 and 6.2Ϯ0.7 L/min for baseline and TYR-25, respectively), but SVR increased significantly by 30% during the TYR-25 dose (Pϭ0.005; Figure 1 ). Systemic infusion of norepinephrine increased systolic and diastolic BP and decreased HR in a dose-dependent manner (ANOVArm; PϽ0.001, for all). The maximal decrease in HR (12Ϯ2 bpm) was twice that produced by tyramine. Norepinephrine did not change forearm blood flow or local vascular resistance significantly (Figure 1 ; Table) but produced a significant increase in SVR (Figure 1) .
Systemic infusions of tyramine and norepinephrine produced similar nonsignificant increases in forearm blood flow and forearm vascular resistance (Figure 2) . For comparison purposes, we also include data reported previously 1 using tyramine later found to be contaminated with dopamine. Tyramine contaminated with dopamine produced an increase in forearm blood flow and a decrease in resistance. This is in contrast to the increase in forearm vascular resistance produced by the cold pressor test (Figure 2 ).
Plasma Dopamine and Other Catecholamines
The concentration of tyramine in the infusate was 2500 g/mL, and it contained 0.15Ϯ0.04 g/mL of dopamine (Ͻ0.01% contamination). Accordingly, the maximal dose of dopamine administered because of this contamination would be 0.082 g/min. The concentrations of dopamine and tyramine at the beginning and end of the study were the same, indicating that there was no in vitro conversion of tyramine to dopamine during study period.
The effect of tyramine and norepinephrine on plasma catecholamines is depicted in the Table. Tyramine produced parallel and dose-dependent increases in plasma norepinephrine and DHPG (Figure 3) . In contrast, intravenous norepinephrine did not increase plasma DHPG despite a significant increase in plasma norepinephrine (Figure 3 ). Plasma concentration of dopamine did not increase during tyramine or norepinephrine infusions (Figure 3) . The monoamine oxidase (MAO) metabolite of dopamine DOPAC increased slightly with tyramine, but this did not reach significance (Table) . The DOPAC/DHPG ratio, which reflects generation and release of dopamine intraneuronal metabolites in relation to norepinephrine metabolites, decreased significantly during tyramine infusion (Table) .
Discussion
In the present study, we demonstrated that intravenous administration of a tyramine preparation, documented to be free of dopamine contamination, does not produce the increase in plasma dopamine or forearm vasodilation reported previously. 1 Therefore, these putative effects of tyramine were caused by contamination of dopamine in commonly used tyramine solutions, as suggested by Goldstein and Holmes. 5 We also found that the hemodynamic effects of intravenous administration of dopamine-free tyramine were similar to those of intravenous norepinephrine; both produced an increase in SVR but did not produce a significant forearm vasoconstriction. These observations are important because tyramine is widely used as a pharmacological tool to evaluate the role of the sympathetic nervous system on human physiology and pathology. The underlying assumption is that tyramine mimics naturally occurring sympathetic activation because it induces the nonexocytotic release of norepinephrine from catecholamine-containing vesicles in sympathetic neurons. In agreement with this assumption, we observed parallel and dose-dependent increases in plasma norepinephrine and DHPG during tyramine infusion. DHPG is an intraneuronal metabolite of norepinephrine formed by MAO. 10 Of interest, tyramine induced a greater increase in DPHG compared with norepinephrine. Tyramine displaces norepinephrine from neuronal vesicles into the axoplasm, and it is likely that some of it is converted to DHPG, and only a portion reaches the circulation.
We initially proposed that the increase in plasma dopamine observed in previous studies could be explained by tyramineinduced release of dopamine from sympathetic neurons. The results presented here prove this hypothesis to be wrong. We found only a small increase in plasma dopamine, and we did not observe an increase in plasma DOPAC, the intraneuronal metabolite of dopamine. These findings do not negate the possibility that tyramine releases dopamine from sympathetic nerve terminals, as reported in the literature. 3 In a recent study, perfusion of tyramine through a microdialysis catheter into the nucleus accumbens of rats induced a 100-fold increase in dopamine dialyzate levels, and this effect was greatly reduced in rats fed a diet deficient in n-3 polyunsaturated fatty acids. 11 These observations suggest that tyramine can induce the release of dopamine, assuming the same tyramine preparation was used in both groups of animals. On the other hand, our results suggest that dopamine release from sympathetic neurons plays a minor role in the overall hemodynamic effect of intravenous tyramine in humans.
It is noteworthy that neither tyramine nor norepinephrine produced a significant increase in forearm vascular resistance. A similar phenomenon is seen when other vasoconstrictors are given intravenously, including angiotensin II. 12 Tyramine and norepinephrine increased SVR significantly, suggesting that other vascular beds have a greater sensitivity to these vasoconstrictors than the forearm. Alternatively, the forearm may be more sensitive to the buffering effects of baroreflexes than other vascular beds. Because of its ready access and ease of measurement, forearm blood flow is frequently used as a surrogate of the effects of vasoactive agents on systemic hemodynamics. However, our observation cast doubt about the usefulness of this approach.
The dopamine-free tyramine preparation used in the present study is commercially available in lyophilized form, which ensures its stability and prevents nonenzymatic oxidation to dopamine. We observed Ͻ0.01% contamination of dopamine in tyramine solutions freshly diluted from this lyophilized form compared with Ϸ1% contamination in our previous preparations of tyramine stored as a saline solution containing sodium metabisulfite as preservative. Care should be taken to avoid dopamine contamination when using tyramine as a pharmacological tool to mimic the effects of naturally occurring sympathetic activation. Even then, we should consider that most stimuli do not elicit a homogeneous sympathetic activation, but a heterogenous one, and that the pattern of activation depends on the stimuli and pathways recruited. For example, the patterns of sympathetic activation produced by the cold pressor test and by tyramine infusion are qualitatively different; the former produces significant forearm vascular resistance, and the latter does not. 1 
Perspectives
We found that intravenous administration of a tyramine preparation free of dopamine contamination produces the expected increases in SVR, BP, and in plasma norepinephrine and its intraneuronal metabolite DHPG but not in plasma dopamine or its intraneuronal metabolite DOPAC. Previous observations of forearm vasodilation induced by tyramine infusions can now be explained by contamination of the infusate by dopamine. Tyramine is used often in clinical studies as a pharmacological tool to assess sympathetic function. The findings reported here are important because the interpretation of previously published studies, including our own, need to reconsider in light of the fact that results may be confounded by dopamine contamination. In future studies, care should be taken in using only dopamine-free tyramine preparations.
